Abstract: The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.

Abstract: A method of state splitting in a state machine includes determining a number N of logic levels, i.e. CLB levels, for each state in a state machine. Number N is equal to N.sub.i-1 +log.sub.k f.sub.i wherein "k" is the number of input lines to a CLB, "i" is a particular node in a particular hierarchial level in the Boolean logic, and "f" is the number of fanin transitions to the particular node. An average number N(AV) as well as a maximum number N(MAX) of CLBs to implement the states in the state machine are also determined. Then, predetermined exit criteria are checked. One exit criterion includes determining that the maximum number N(MAX) is not associated with a state register, but is instead associated with an output, for example. Another exit criterion includes providing a ratio by dividing the maximum number N(MAX) by the average number N(AV). If the ratio is less than or equal to a split-factor, then this exit criterion is met. In one embodiment, the split factor is between 1.5 and 2.0.